Literature DB >> 12844216

A survival-based scoring-system for initial graft function following orthotopic liver transplantation.

Michael Heise1, Utz Settmacher, Robert Pfitzmann, Ute Wünscher, Andrea Raffaela Müller, Sven Jonas, Peter Neuhaus.   

Abstract

Initial graft function following orthotopic liver transplantation is a major determinant of postoperative survival and morbidity. Despite several efforts to provide scoring-systems for initial graft function, there is still a lack of a generally accepted classification scheme. The previously published systems assessed initial graft function based on the first postoperative days or weeks using liver-related laboratory parameters. It was shown that in most cases the scoring-systems did not correlate with patient survival. We intended to refine the definition of initial graft function in order to provide a survival based classification system. In a retrospective analysis of 761 patients following primary liver transplantation, a new scoring-system for early postoperative graft function was developed. Statistically significant differences in long term survival were calculated for ALAT, ASAT, bile production and prothrombin activity on days 1, 3, 7, 14. Points were then assigned according to the degree of survival: improved survival=1 point, poor survival=2 points. Patients were split into three groups corresponding to initially good, moderate and poor function. Applying this score, early and late patient survival rates and incidence of initial non-function were statistically significantly different. This was in contrast to the Gonzalez and the Ploeg-Maring classification scales, which are based on arbitrarily chosen cutoff levels. Retransplantation rates and postoperative morbidity were comparable both for the new and the older systems. We can conclude that the presented refined scoring-system for initial graft function provides a significant correlation to patient survival and initial non-function. We recommend the refined system for future studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12844216     DOI: 10.1007/s00147-003-0625-z

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

1.  Effects of low central venous pressure during preanhepatic phase on blood loss and liver and renal function in liver transplantation.

Authors:  Zhi-Ying Feng; Xiao Xu; Sheng-Mei Zhu; Berthold Bein; Shu-Sen Zheng
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

Review 2.  Predictive factors of short term outcome after liver transplantation: A review.

Authors:  Giuliano Bolondi; Federico Mocchegiani; Roberto Montalti; Daniele Nicolini; Marco Vivarelli; Lesley De Pietri
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

3.  Epsilon-aminocaproic acid improves postrecirculation hemodynamics by reducing intraliver activated protein C consumption in orthotopic liver transplantation.

Authors:  H Y Kong; X H Wen; S Q Huang; S M Zhu
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

4.  Oxygen persufflation as adjunct in liver preservation (OPAL): study protocol for a randomized controlled trial.

Authors:  Thomas Minor; Carolin Pütter; Anja Gallinat; Claudia Ose; Gernot Kaiser; Andre Scherag; Jürgen Treckmann; Andreas Paul
Journal:  Trials       Date:  2011-10-28       Impact factor: 2.279

5.  A non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients.

Authors:  Fuat Hakan Saner; Knut Nowak; Dieter Hoyer; Peter Rath; Ali Canbay; Andreas Paul; Michael Koldehoff; Ahmet Elmaağaclı
Journal:  BMC Gastroenterol       Date:  2014-01-06       Impact factor: 3.067

6.  The PRAISE study: a prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of iloprost in the early postoperative period after liver transplantation (ISRCTN12622749).

Authors:  Erik Bärthel; Falk Rauchfuss; Heike Hoyer; Maria Breternitz; Karin Jandt; Utz Settmacher
Journal:  BMC Surg       Date:  2013-01-29       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.